Last reviewed · How we verify

NCT07445386

Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain

Recruiting now NA Last updated 3 March 2026
What this trial tests

NA trial testing transdiscal splanchnic neurolysis in Cancer Pain in 56 participants. Currently enrolling.

Timeline
16 February 2026
Primary endpoint
16 August 2026
16 September 2026

Quick facts

Lead sponsorAnkara Etlik City Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment56
Start date16 February 2026
Primary completion16 August 2026
Estimated completion16 September 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara Etlik City Hospital

Who can join

18 and older, any sex, with Cancer Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare the efficacy of fluoroscopy-guided paravertebral (PV) and transdiscal (TD) approaches for splanchnic nerve neurolysis in patients with upper abdominal cancer-related pain (e.g., gastric, pancreatic, and hepatic malignancies). Treatment response will be assessed using the Numerical Rating Scale (NRS), and the impact of both techniques on quality of life will be evaluated with the EORTC QLQ-C30 questionnaire.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer Pain

Currently open trials in the same condition.

Other Ankara Etlik City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07445386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing